GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vireo Growth Inc (OTCPK:VREOF) » Definitions » Beta

VREOF (Vireo Growth) Beta : 0.65 (As of Oct. 31, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Vireo Growth Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-10-31), Vireo Growth's Beta is 0.65.


Vireo Growth Beta Historical Data

The historical data trend for Vireo Growth's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vireo Growth Beta Chart

Vireo Growth Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1.53 0.44

Vireo Growth Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.66 0.44 0.63 0.46

Competitive Comparison of Vireo Growth's Beta

For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vireo Growth's Beta Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's Beta distribution charts can be found below:

* The bar in red indicates where Vireo Growth's Beta falls into.



Vireo Growth Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Vireo Growth  (OTCPK:VREOF) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Vireo Growth Beta Related Terms

Thank you for viewing the detailed overview of Vireo Growth's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Vireo Growth Business Description

Traded in Other Exchanges
Address
207 South 9th Street, Minneapolis, Minneapolis, MN, USA, 55402
Vireo Growth Inc is a cannabis company whose mission is to provide safe access, quality products, and value to its customers while supporting its local communities through active participation and restorative justice programs.
Executives
Chicago Atlantic Credit Opportunities, Llc 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Manager, Llc 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Gp Holdings, Llc 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Group, Lp 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Group Gp, Llc 10 percent owner 420 N WABASH AVE STE 500, CHICAGO IL 60611
Chicago Atlantic Advisers, Llc 10 percent owner 420 NORTH WABASH AVENUE, SUITE 500, CHICAGO IL 60611
Joshua Rosen director 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Victor E. Mancebo director C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Christian Gonzales Ocasio officer: Chief Operating Officer C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Amber Holly Shimpa director, officer: Chief Administrative Officer C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Patrick Peters officer: EVP of Retail C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
J Michael Schroeder officer: General Counsel & CCO 3680 VICTORA STREET N, SHOREVIEW MN 55126
John Andrew Heller officer: Chief Financial Officer C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Ross Michael Hussey director C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402
Judd Theodore Nordquist director C/O VIREO HEALTH INTERNATIONAL, INC., 207 SOUTH 9TH STREET, MINNEAPOLIS MN 55402